CCKBR and neoplasm: Previous rhCCK derivatives, [19F]F-[177Lu-]Lu-(R)-DOTAGA-rhCCK-9 and -16, revealed 3- to 8-fold increased activity levels in the tumor compared to [177Lu]Lu-DOTA-PP-F11N at 24 h p.i., respectively, despite a noticeably lower CCK-2R affinity.